Orexigen Therapeutics (OREX) 5.44 $OREX
Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:50AM CDT
Orexigen Therapeutics reported a net loss of 23 cents per share in the first quarter of 2014.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Fri May 09, 3:30PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 14th at 3 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Orexigen Therapeutics Reports Corporate and Financial Results for the First Quarter Ended March 31, 2014
PR Newswire - Thu May 08, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the first quarter ended March 31, 2014.
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Downtrend Call Working As Orexigen Therapeutics Stock Falls 14.5% (OREX)
Comtex SmarTrend(R) - Wed May 07, 9:28AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 1 month, Orexigen Therapeutics has returned 14.47% as of today's recent price of $5.44.
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Orexigen Therapeutics to Host First Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Thu May 01, 7:30AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter 2014, on Thursday, May 8, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Biotechs' Rocky Road
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 4:28PM CDT
Biotechs have taken a bit of a beating of late, with the Nasdaq Biotechnology Index off 18% from its high in February and flat for the year. There doesn't seem to be any one thing to blame. Instead it's a combination of little things like worry...
Shares of OREX Down 13.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 22, 9:27AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 4 weeks, Orexigen Therapeutics has returned 13.54% as of today's recent price of $5.50.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Orexigen Therapeutics Down 17.5% Since SmarTrend Downtrend Call (OREX)
Comtex SmarTrend(R) - Mon Apr 14, 9:15AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 2 weeks, Orexigen Therapeutics has returned 17.45% as of today's recent price of $5.25.
Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
M2 - Thu Apr 10, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2442zl/obesity) has announced the addition of the "Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity" report to their offering. The current market, which is dominated by off-patent orlistat products, is expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from approximately $750m in 2012 to approximately $2.6 billion in 2019 Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and the authors believe that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, the authors expect the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Pipeline - Market Forecasts - Licensing and Co-Development Deals - Appendix Products Mentioned - Cametor, Norgine BV - Contrave, Orexigen Therapeutics - Victoza, Novo Nordisk - Tesofensine (NeuroSearch) For more information visit http://www.researchandmarkets.com/research/2442zl/obesity
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Global Contrave (Obesity) Market 2014 - Forecast and Apportunities to 2022
M2 - Wed Apr 02, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tc6jzb/contrave) has announced the addition of the "Contrave (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Contrave for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Contrave 9 Appendix For more information visit http://www.researchandmarkets.com/research/tc6jzb/contrave
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:50AM CDT
Orexigen Therapeutics reported a net loss of 23 cents per share in the first quarter of 2014.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
PR Newswire - Fri May 09, 3:30PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 14th at 3 p.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
Orexigen Therapeutics Reports Corporate and Financial Results for the First Quarter Ended March 31, 2014
PR Newswire - Thu May 08, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the first quarter ended March 31, 2014.
Technical Recap on Biotech Equities -- Research on Hemispherx Biopharma, Orexigen Therapeutics, Dynavax Technologies, and Synergy Pharma
PR Newswire - Thu May 08, 1:30PM CDT
On Wednesday, May 07, 2014, the NASDAQ Composite ended at 4,067.67, down 0.32%, the Dow Jones Industrial Average finished the day 0.72% higher at 16,518.54, and the S&P 500 closed at 1,878.21, up 0.56%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.01, up 0.23%, and the index has advanced 0.50% in the last one month. Investor-Edge has initiated coverage on the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Orexigen Therapeutics Inc. (NASDAQ: OREX), Dynavax Technologies Corporation (NASDAQ: DVAX) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on HEB, OREX, DVAX and SGYP can be downloaded upon signing up at:
Downtrend Call Working As Orexigen Therapeutics Stock Falls 14.5% (OREX)
Comtex SmarTrend(R) - Wed May 07, 9:28AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 1 month, Orexigen Therapeutics has returned 14.47% as of today's recent price of $5.44.
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
Biotech 101: Valuing Binary Events
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:18PM CDT
Binary events are the lifeblood of investing in biotech companies. A clinical trial result or Food and Drug Administration decision can send the company's value up or down considerably. And not necessarily the same amount in either direction; the...
Orexigen Therapeutics to Host First Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Thu May 01, 7:30AM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter 2014, on Thursday, May 8, 2014 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time).
Biotechs' Rocky Road
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 25, 4:28PM CDT
Biotechs have taken a bit of a beating of late, with the Nasdaq Biotechnology Index off 18% from its high in February and flat for the year. There doesn't seem to be any one thing to blame. Instead it's a combination of little things like worry...
Shares of OREX Down 13.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 22, 9:27AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 4 weeks, Orexigen Therapeutics has returned 13.54% as of today's recent price of $5.50.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Orexigen Therapeutics Down 17.5% Since SmarTrend Downtrend Call (OREX)
Comtex SmarTrend(R) - Mon Apr 14, 9:15AM CDT
SmarTrend identified a Downtrend for Orexigen Therapeutics (NASDAQ:OREX) on March 28th, 2014 at $6.36. In approximately 2 weeks, Orexigen Therapeutics has returned 17.45% as of today's recent price of $5.25.
Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
M2 - Thu Apr 10, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2442zl/obesity) has announced the addition of the "Global Obesity Therapeutics Market 2013-2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity" report to their offering. The current market, which is dominated by off-patent orlistat products, is expected to grow at a modest Compound Annual Growth Rate (CAGR) of 20.7% from approximately $750m in 2012 to approximately $2.6 billion in 2019 Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical's Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and the authors believe that only one, Vivus' Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, the authors expect the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals' negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Key Topics Covered: - Tables & Figures - Introduction - Marketed Products - Pipeline - Market Forecasts - Licensing and Co-Development Deals - Appendix Products Mentioned - Cametor, Norgine BV - Contrave, Orexigen Therapeutics - Victoza, Novo Nordisk - Tesofensine (NeuroSearch) For more information visit http://www.researchandmarkets.com/research/2442zl/obesity
Health Care Sector Stocks under Review -- Research on Endo Intl., Dynavax Technologies, Forest Laboratories, and Orexigen Therapeutics
PR Newswire - Wed Apr 09, 9:14AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average advanced 0.06% to 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 4.04% in the last one month. Investor-Edge has initiated coverage on the following equities: Endo International PLC (NASDAQ: ENDP), Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX) and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free technical research on ENDP, DVAX, FRX and OREX can be downloaded upon signing up at:
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Global Contrave (Obesity) Market 2014 - Forecast and Apportunities to 2022
M2 - Wed Apr 02, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tc6jzb/contrave) has announced the addition of the "Contrave (Obesity) - Forecast and Market Analysis to 2022" report to their offering. After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients. Contrave is an investigational medication being evaluated for weight loss by San Diego, California-based Orexigen Therapeutics in partnership with Takeda Pharmaceuticals in Osaka, Japan. Takeda has already paid a $50m upfront payment to Orexigen and will be eligible to receive up to $1 billion for achieving certain regulatory and sales milestones. Takeda has obtained exclusive marketing rights for the markets in the United States, Canada and Mexico, while Orexigen maintains the right to co-promote Contrave in the US. Scope - Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Contrave including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Contrave for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil and Canada Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Contrave 9 Appendix For more information visit http://www.researchandmarkets.com/research/tc6jzb/contrave
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
George Budwell, The Motley Fool - Motley Fool - Sun Mar 30, 3:30PM CDT
GlaxoSmithKline announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills that...
